Background While curable at early stages, few treatment options exist for advanced melanoma. Currently, no consensus exists regarding the optimal surveillance strategy for patients after resection. The objectives of this study were to identify patterns of metastatic recurrence, to determine the influence of metastatic site on survival, and to identify high-risk periods for recurrence. Methods A retrospective review of the Duke Melanoma Database from 1970 to 2004 was conducted that focused on patients who were initially diagnosed without metastatic disease. The time to first recurrence was computed from the date of diagnosis, and the associated hazard function was examined to determine the peak risk period of recurrence. Metastatic sites were coded by the American Joint Committee on Cancer (AJCC) system including local skin, distant skin and nodes (M1a), lung (M1b), and other distant (M1c). Results Of 11,615 patients initially diagnosed without metastatic disease, 4616 (40%) had at least one recurrence. Overall the risk of initial recurrence peaked at 12 months. The risk of initial recurrence at the local skin, distant skin, and nodes peaked at 8 months, and the risk at lung and other distant sites peaked at 24 months. Patients with a cutaneous or nodal recurrence had improved survival compared to other recurrence types. Conclusions The risk of developing recurrent melanoma peaked at one year, and the site of first recurrence had a significant impact on survival. Defining the timing and expected patterns of recurrence will be important in creating an optimized surveillance strategy for this patient population.
References
[1]
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.
[2]
Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27: 6199–6206.
[3]
Morton RL, Craig JC, Thompson JF (2009) The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol 16: 571–577.
[4]
Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, et al. (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103: 129–142.
[5]
Brenner DJ, Hall EJ (2007) Computed tomography--an increasing source of radiation exposure. N Engl J Med 357: 2277–2284.
[6]
Weiss M, Loprinzi CL, Creagan ET, Dalton RJ, Novotny P, et al. (1995) Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 274: 1703–1705.
[7]
Turner RM, Bell KJ, Morton RL, Hayen A, Francken AB, et al. (2011) Optimizing the Frequency of Follow-Up Visits for Patients Treated for Localized Primary Cutaneous Melanoma. J Clin Oncol
[8]
Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28: 3042–3047.
[9]
Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, et al. SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD. Available: http://seer.cancer.gov/csr/1975_2008/.Based on November 2010 SEER data submission, posted to the SEER web site , 2011.
[10]
Crowley NJ, Seigler HF (1990) Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 212: 173–177.
[11]
Hansel G, Schonlebe J, Haroske G, Wollina U (2010) Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). A single-centre analysis of 1881 patients with a follow-up of 10 years or more. J Eur Acad Dermatol Venereol 24: 833–836.
[12]
Shaw HM, Beattie CW, McCarthy WH, Milton GW (1985) Late relapse from cutaneous stage I malignant melanoma. Arch Surg 120: 1155–1159.
[13]
Callaway MP, Briggs JC (1989) The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg 42: 46–49.
[14]
Koh HK, Sober AJ, Fitzpatrick TB (1984) Late recurrence (beyond ten years) of cutaneous malignant melanoma. Report of two cases and a review of the literature. JAMA 251: 1859–1862.
[15]
McCarthy WH, Shaw HM, Thompson JF, Milton GW (1988) Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 166: 497–502.
[16]
Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF (1992) Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 28: 45–49.
[17]
Tas F (2012) Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors. J Oncol 2012: 647684.
[18]
Tejera-Vaquerizo A, Barrera-Vigo MV, Fernandez-Canedo I, Blazquez-Sanchez N, Mendiola-Fernandez M, et al. (2007) [Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma]. Actas Dermosifiliogr 98: 531–538.
[19]
Carlson GW, Page AJ, Cohen C, Parker D, Yaar R, et al. (2008) Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg 248: 378–386.
[20]
Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, et al. (1998) Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16: 2253–2260.
[21]
Dalal KM, Patel A, Brady MS, Jaques DP, Coit DG (2007) Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 14: 1934–1942.
[22]
Zogakis TG, Essner R, Wang HJ, Foshag LJ, Morton DL (2007) Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol 14: 1604–1611.
[23]
Petersen RP, Hanish SI, Haney JC, Miller CC 3rd, Burfeind WR Jr., et al (2007) Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma.[see comment]. Journal of Thoracic & Cardiovascular Surgery 133: 104–110.
[24]
Nieweg OE, Kroon BB (2006) The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am 15: 319–330.
[25]
Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, et al. (2007) Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 14: 1924–1933.
